Novavax Reports Enduring Covid Immune Response Six Months After Vaccination

Maryland-based vaccine producer Novavax mentioned Monday that its Covid vaccine confirmed robust safety in opposition to Covid-19 an infection over a six month interval following the second dose from November 2020 to Could 2021. The vaccine confirmed total efficacy of 82.7% in opposition to Covid an infection and 100% efficacy in opposition to extreme illness. 

“We’re inspired to see that our Covid-19 vaccine maintains a excessive stage of sturdy efficacy,” mentioned Gregory Glenn, the corporate’s president of vaccine R&D. “And continues to exhibit a reassuring security profile on this prolonged timeline.”

Though the six-month research, which occurred within the U.Okay, mirrored a interval wherein alpha was the dominant variant, scientific research within the U.S. in the course of the delta wave discovered that the vaccine maintained 82% efficacy in opposition to that variant. Lab research released by the company additionally discovered that the vaccine is lively in opposition to the omicron variant. 

Novavax’s vaccine is completely different from different vaccines presently out there in america. Its vaccine makes use of a nanoparticle that mimics the coronavirus’ spike protein. These particles are injected into the affected person together with a chemical that helps stimulate the immune system. The nanoparticles trigger the affected person’s immune system to develop antibodies in opposition to the virus that causes Covid. 

To this point, Novavax’s vaccine has been licensed in over 38 nations, together with Canada, the UK, Australia and the European Union. It’s additionally been licensed by the World Well being Group. The corporate filed for emergency use authorization with the FDA on the finish of January. 

Along with the brand new vaccine information, the corporate additionally introduced its 4Q earnings. The corporate’s revenues topped over $1.1 billion, it reported, up from its 2020 revenues of $476 million. Web losses for the 12 months had been $1.7 billion, reflecting the $2.5 billion improvement spend concerned with the corporate scaling up and manufacturing doses of its Covid vaccine. 

For 2022, the corporate expects $4 to $5 billion in income, reflecting contact funds for promoting vaccine doses. The corporate can be transferring ahead creating different new vaccines, together with one for flu and a mixture Covid/flu vaccine. Earlier this month, analysts at Jeffries revealed a word estimating that the corporate’s Covid vaccine will likely be a permanent income, bringing in $2.5-$4 billion per 12 months.

Full protection and reside updates on the Coronavirus